Table 3.
Initiation of positive coverage of next-generation tumor sequencing by year.*
| Year | Percentage of payers who initiated positive coverage policy for sequencing (n = 69) | Commercial enrollee population covered by new coverage in this year† |
|---|---|---|
| 2015 | 1 | 522 570 |
| 2016 | 4 | 23 961 190 |
| 2017‡ | 20 | 38 690 818 |
| 2018 | 17 | 64 014 700 |
| 2019§ | 4 | 910 275 |
| Total | 48 | 128 099 553 |
Sequencing indicates next-generation tumor sequencing.
*
Positive coverage policy states coverage of sequencing for any indication, any sequencing test(s), and any policy stipulation (eg, with or without prior authorization).
†
Commercial population is reported based on the data available in the Canary Insights database as of 04/01/2019.
‡
Year of Center for Medicare and Medicaid Services (CMS) announcement of the draft National Coverage Determination (NCD).
§
Includes coverage through April 1, 2019.